Korean Firms Readying To Compete In Global GLP-1 Obesity Space
Hanmi Leading With Phase III Trial
With Hanmi's progress in changing the main indication of its GLP-1 contender efpeglenatide to obesity, Scrip takes an infographic look at what other Korean firms are doing in both this indication and elsewhere in the GLP-1 space.
